

Gambia

Support for Vaccine: Meningococcal type A This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Gambia						
2. Vaccine grant number:	17-GMB-08j-Y, 1721-GMB-28a-X						
3. Date of Decision Letter:	9/30/2019						
4. Date of the Partnership Framework Agreement:	Sunday, February 3, 2013						
5. Programme title:	New Vaccine Support (NVS), Meningococcal type A, Routine						
6. Vaccine type:	Meningococcal type A						
7. Requested product presentation and formulation of vaccine:	Meningococcal type A, 10 dose(s) per vial, LYOPHILISED						
8. Programme Duration:¹	2017-2021						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2017-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	75,500	25,500	27,000	-	-	-	128,000
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2017	17-GMB-08j-Y	100,000				
	Disbursement						
	Disbursement date		Amount (US\$)				
	13 June, 2017		100,000				
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2017-2019	2020	2021				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Number of vaccine doses		44,600	-
Annual Amounts (US\$)	75,500	25,500	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	25,000	26,500	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	13,400	14,096	-	-	-
Total co-financing payments (US\$) (including freight)	14,000	15,000	-	-	-

In order to mitigate risks of stocking out in 2020, co-financing obligation associated with this program should be fulfilled by September 2020

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	31 March 2020 15 May 2020

<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>
<p>18. Financial clarifications: Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>	
<p>19. Other conditions:</p> <p>Not applicable</p>	

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30/09/2019